CCR2-engineered mesenchymal stromal cells accelerate diabetic wound healing by restoring immunological homeostasis

Shuhong Kuang,Feng He,Guihua Liu,Xiangzhou Sun,Jian Dai,Ani Chi,Yali Tang,Zhuoran Li,Yong Gao,Chunhua Deng,Zhengmei Lin,Haipeng Xiao,Min Zhang
DOI: https://doi.org/10.1016/j.biomaterials.2021.120963
IF: 14
2021-08-01
Biomaterials
Abstract:<p>Impaired wound healing presents great health risks to patients. While encouraging, the current clinical successes of mesenchymal stromal cell (MSC)-based therapies for tissue repair have been limited. Genetic engineering could endow MSCs with more robust regenerative capacities. Here, we identified that C-C motif chemokine receptor 2 (CCR2) overexpression enhanced the targeted migration and immunoregulatory potential of MSCs in response to C-C motif chemokine ligand 2 (CCL2) in vitro. Intravenously infusion of CCR2-engineered MSCs (MSCs<sup>CCR2</sup>) exhibited improved homing efficiencies to injured sites and lungs of diabetic mice. Accordingly, MSC<sup>CCR2</sup> infusion inhibited monocyte infiltration, reshaped macrophage inflammatory properties, prompted the accumulation of regulatory T cells (Treg cells) in injured sites, and reshaped systemic immune responses via the lung and spleen in mouse diabetic wound models. In summary, CCR2-engineered MSCs restore immunological homeostasis to accelerate diabetic wound healing via their improved homing and immunoregulatory potentials in response to CCL2. Therefore, these findings provide a novel strategy to explore genetically engineered MSCs as tools to facilitate tissue repair in diabetic wounds.</p>
engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?